BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Moxley RA, Francis DH, Tamura M, Marx DB, Santiago-Mateo K, Zhao M. Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model. Toxins (Basel) 2017;9:E49. [PMID: 28134751 DOI: 10.3390/toxins9020049] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Kakoullis L, Papachristodoulou E, Chra P, Panos G. Shiga toxin-induced haemolytic uraemic syndrome and the role of antibiotics: a global overview. Journal of Infection 2019;79:75-94. [DOI: 10.1016/j.jinf.2019.05.018] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
2 Henrique IDM, Sacerdoti F, Ferreira RL, Henrique C, Amaral MM, Piazza RMF, Luz D. Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives. Front Cell Infect Microbiol 2022;12:825856. [DOI: 10.3389/fcimb.2022.825856] [Reference Citation Analysis]
3 Lodato PB. The effect of two ribonucleases on the production of Shiga toxin and stx-bearing bacteriophages in Enterohaemorrhagic Escherichia coli. Sci Rep 2021;11:18372. [PMID: 34526533 DOI: 10.1038/s41598-021-97736-z] [Reference Citation Analysis]
4 Mühlen S, Dersch P. Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli. Front Cell Infect Microbiol 2020;10:169. [PMID: 32435624 DOI: 10.3389/fcimb.2020.00169] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
5 Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
6 Harkins VJ, Mcallister DA, Reynolds BC. Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome. Curr Pediatr Rep 2020;8:16-25. [DOI: 10.1007/s40124-020-00208-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Rivero MA, Krüger A, Rodríguez EM, Signorini Porchietto ML, Lucchesi PMA. Seropositivity to Shiga toxin 2 among Argentinian urban and rural residents. Association with sociodemographic and exposure factors. J Public Health (Oxf) 2021:fdab405. [PMID: 34969078 DOI: 10.1093/pubmed/fdab405] [Reference Citation Analysis]
8 Moxley RA. Special Issue: Shiga Toxin-Producing Escherichia coli. Microorganisms 2020;9:E1. [PMID: 33374893 DOI: 10.3390/microorganisms9010001] [Reference Citation Analysis]
9 Lu Z, Liu Z, Li X, Qin X, Hong H, Zhou Z, Pieters RJ, Shi J, Wu Z. Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli. ACS Infect Dis 2022;8:321-9. [PMID: 35015516 DOI: 10.1021/acsinfecdis.1c00456] [Reference Citation Analysis]
10 Sakari M, Laisi A, Pulliainen AT. Exotoxin-Targeted Drug Modalities as Antibiotic Alternatives. ACS Infect Dis 2022;8:433-56. [PMID: 35099182 DOI: 10.1021/acsinfecdis.1c00296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]